Abstract
The relationship between p53 gene status and the expression of DR5 and Fas was evaluated as a function of sensitivity of 11 acute lymphoblastic leukemia cell lines to adriamycin, etoposide, vincristine, methotrexate and dexamethasone. There was up to a 37-fold increase in expression of DR5 following treatment with ADR or VP-16 only in cells with wt p53. A direct correlation was observed between enhanced DR5 expression and sensitivity to ADR and VP-16. There was no induction of DR5 following treatment with VCR, MTX or DEX. There was up to a 51-fold increase in the median level of expression of Fas following treatment with ADR and VP-16, and unlike DR5 this occurred in cells with either wild-type or mutant p53. Nevertheless, a direct correlation was observed between Fas expression and drug-sensitivity. Conversely, there was only a two-fold increase in expression of Fas after exposure to VCR, MTX and DEX. These findings suggest that DR5 mediates sensitivity to ADR and VP-16 in a p53-dependent manner, whereas, Fas appears to mediate sensitivity to these two drugs independent of p53 status. DR5 and Fas do not appear to play a major role as determinants of chemosensitivity to VCR, MTX and DEX.
References
Jan 1, 1980·International Review of Cytology·A H WyllieA R Currie
Jan 27, 1995·Cell·T Miyashita, J C Reed
Mar 10, 1995·Science·C B Thompson
Sep 1, 1993·Chemical Research in Toxicology·A H Corbett, N Osheroff
Aug 27, 1993·Cell·Z N OltvaiS J Korsmeyer
May 1, 1996·Nature Medicine·C FriesenK M Debatin
Feb 1, 1997·The Journal of Clinical Investigation·M MüllerP R Galle
Feb 13, 1997·Nature·C YinT Van Dyke
Jun 4, 1997·Journal of the National Cancer Institute·O MicheauM T Dimanche-Boitrel
Aug 1, 1997·Nature Genetics·C M Knudson, S J Korsmeyer
Aug 8, 1997·Science·G PanV M Dixit
Aug 8, 1997·Science·J P SheridanA Ashkenazi
Nov 5, 1997·The Journal of Biological Chemistry·M MacFarlaneE S Alnemri
Nov 5, 1997·Nature Genetics·G S WuW S el-Deiry
Nov 22, 1997·Leukemia·C FriesenK M Debatin
Jan 7, 1998·Science·E H ChengJ M Hardwick
Feb 12, 1998·The Journal of Biological Chemistry·H Zha, J C Reed
Jun 4, 1998·Biochemical and Biophysical Research Communications·N Fujita, T Tsuruo
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Aug 28, 1998·Science·D R Green, J C Reed
Sep 16, 1998·Leukemia·A M YamamotoH J Garchon
Oct 9, 1998·Oncogene·D E WoodE W Newcomb
Nov 21, 1998·Leukemia·M ZhouH W Findley
Dec 8, 1998·The Journal of Experimental Medicine·M MüllerP H Krammer
Mar 11, 1999·Cancer Letters·T AraiY Yuasa
Mar 13, 1999·The Journal of Biological Chemistry·D E Wood, E W Newcomb
Jun 22, 1999·The Journal of Biological Chemistry·B W Johnson, L H Boise
Jul 20, 1999·The Journal of Biological Chemistry·D G KirschJ M Hardwick
Nov 26, 1999·Leukemia Research·V LamG J Goldenberg
Apr 25, 2000·Oncogene·R Takimoto, W S El-Deiry
Citations
Mar 3, 2011·Cell Death & Disease·D MeleyV Sée
Aug 30, 2008·Srpski arhiv za celokupno lekarstvo·Tatjana Stankovic, Eliot Marston
Oct 19, 2010·Haematologica·Philip SaundersLinda J Bendall
Dec 25, 2010·Journal of Biochemical and Molecular Toxicology·Maged BarakatJackleen Raafat
Oct 31, 2009·Journal of Cellular Physiology·Giorgio ZauliPaola Secchiero
Mar 17, 2007·Molecular Cancer Therapeutics·Hyunki KimKurt R Zinn